• P Bouzat, G Francony, M Oddo, and J-F Payen.
• Pôle anesthésie réanimation, hôpital A. Michallon, CHU de Grenoble, 38000 Grenoble, France; Université Joseph-Fourier, 38000 Grenoble, France; Inserm U836, institut des neurosciences de Grenoble, 38000 Grenoble, France. Electronic address: pbouzat@chu-grenoble.fr.
• Ann Fr Anesth Reanim. 2013 Nov 1;32(11):787-91.

AbstractTherapeutic hypothermia (TH) is considered a standard of care in the post-resuscitation phase of cardiac arrest. In experimental models of traumatic brain injury (TBI), TH was found to have neuroprotective properties. However, TH failed to demonstrate beneficial effects on neurological outcome in patients with TBI. The absence of benefits of TH uniformly applied in TBI patients should not question the use of TH as a second-tier therapy to treat elevated intracranial pressure. The management of all the practical aspects of TH is a key factor to avoid side effects and to optimize the potential benefit of TH in the treatment of intracranial hypertension. Induction of TH can be achieved with external surface cooling or with intra-vascular devices. The therapeutic target should be set at a 35°C using brain temperature as reference, and should be maintained at least during 48 hours and ideally over the entire period of elevated intracranial pressure. The control of the rewarming phase is crucial to avoid temperature overshooting and should not exceed 1°C/day. Besides its use in the management of intracranial hypertension, therapeutic cooling is also essential to treat hyperthermia in brain-injured patients. In this review, we will discuss the benefit-risk balance and practical aspects of therapeutic temperature management in TBI patients.Copyright © 2013 Société française d’anesthésie et de réanimation (Sfar). Published by Elsevier SAS. All rights reserved.

27 keywords...

hide…